Sylentis' dry eye drug misses primary goals in phase 3

A phase 3 trial of Sylentis’ dry eye disease candidate tivanisiran has missed its primary endpoints. The PharmaMar subsidiary failed to link the siRNA eye drops to improved scores on scales of ocular pain and corneal staining compared to artificial tears.